Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Pancreatic Cell News 7.33 August 23, 2016 | |
 | |
| |
TOP STORYInvestigators hypothesized that activation of β1-adrenergic receptors localized to ghrelin cells is required for caloric restriction-associated ghrelin release and the ensuing protective glucoregulatory response. [J Clin Invest] Full Article | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISScientists have generated time-resolved profiles of enhancer and transcriptional activity in response to glucose in the INS-1E pancreatic β cell line. [Cell Rep] Full Article | Graphical Abstract Controlled Release of Liraglutide Using Thermogelling Polymers in Treatment of Diabetes In treatment of diabetes, it is much desired in clinics and challenging in pharmaceutics and material science to set up a long-acting drug delivery system. The authors aimed at constructing a new delivery system using thermogelling PEG/polyester copolymers. [Sci Rep] Full Article PANCREATIC CANCERYes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma Researchers identified Yes-associated protein as a critical regulator of the immunosuppressive microenvironment in both mouse and human pancreatic ductal adenocarcinoma. [Oncogene] Abstract MMP-9 is a protease found to be upregulated in virtually all malignant tumors. Scientists hypothesized that its presence can provide a de-shielding activity for targeted delivery of drugs by nanoparticles in pancreatic cancer. [J Control Release] Abstract Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy Researchers observed Bazedoxifene inhibited STAT3 phosphorylation and STAT3 DNA binding, induced apoptosis, and suppressed tumor growth in pancreatic cancer cells with persistent IL-6/GP130/STAT3 signaling in vitro and in vivo. [Mol Cancer Ther] Abstract The anticancer effects of triacetylresveratrol which has higher bioavailability have not been well established. Scientists comparatively evaluated the effects on cell proliferation, apoptosis and the molecular changes in STAT3, NFκB and apoptotic signaling pathways in pancreatic cancer cells. [Sci Rep] Full Article CXCL12-CXCR7 Axis Contributes to the Invasive Phenotype of Pancreatic Cancer Chemokine (C-X-C motif) receptor 7 (CXCR7) and its ligand, chemokine (C-X-C motif) ligand 12 (CXCL12), were established to be involved in biological behaviors and associated with prognosis in many cancers. However, effects, underlying mechanisms of CXCL12-CXCR7 axis in invasive phenotype of pancreatic cancer and its clinicopathologic significances have not been comprehensively explored. [Oncotarget] Full Article To better understand the relationship that Kras activation has on miRNA expression, the authors profiled the expression of 629 miRNAs in RNA isolated from the pancreas of control, young, and old P48+/Cre;LSL-KRASG12D as well as PDX-1-Cre;LSL-KRASG12D mice. [Funct Integr Genomics] Abstract | |
| |
| |
REVIEWSNanomedicine Strategies to Overcome the Pathophysiological Barriers of Pancreatic Cancer The reviewers discuss the approaches to nanomedicine that have been pursued to date and those that are the focus of ongoing research, and outline their potential, as well as the key challenges that must be overcome. [Nature Reviews Clinical Oncology] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
INDUSTRY NEWSKadimastem announced that following success in the first stage of trials held under the agreement entered on November 24, 2015, an addendum was signed which sets out the timetable for starting feasibility studies in animals in the course of next month. The first stage involved joint trials in which optimization of the conditions was carried out and it was shown that the insulin-secreting cells developed by Kadimastem demonstrate activity which is similar to human pancreatic islet cells. [Kadimastem] Press Release vTv Therapeutics Inc. announced the completion of enrollment of the company’s Phase II LOGRA (aLlosteric Oral Glp1 Receptor Agonist) study, a randomized, double-blind, placebo-controlled, parallel group trial of TTP273. TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential. [vTv Therapeutics Inc. (Business Wire)] Press Release | |
| |
POLICY NEWSPutin Appoints Church Historian as Science Minister Russian President Vladimir Putin has appointed a church historian as the country’s new science and education minister. The president announced that Olga Vasilyeva would succeed the current science minister, Dmitry Livanov, who will become presidential envoy on trade and economic relations with Ukraine, according to the Russian news agency Interfax. [Nature News] Editorial Obama’s Science Legacy: Betting Big on Biomedical Science Ambitious bids to map the brain and cure cancer have not boosted overall research funding. [Nature News] Editorial US Personalized-Medicine Industry Takes Hit from Supreme Court Rejections for US patents related to personalized medicine have spiked after recent Supreme Court decisions tightened the rules for such claims, an analysis of more than 39,000 patent applications reveals. [Nature News] Editorial Chemistry Group Throws Out Election Results after Fears of Vote Rigging Members of the Society of Biological Inorganic Chemistry are reacting with puzzlement and shock after learning that the results of a recent online leadership election have been thrown out because of voting irregularities—raising concerns over possible manipulation. [ScienceInsider] Editorial Updated: Companies Settle Gene Technology Patent Fight That Was Shrouded in Mystery Illumina Inc. and Oxford Nanopore Technologies have reached a settlement in this legal battle, according to a U.S. International Trade Commission document released last week. Oxford has agreed not to import or sell any product containing a pore with an amino acid sequence at least 68% similar to Mycobacterium smegmatis porin — the protein at the heart of Illumina’s infringement claim — and to destroy any inventory of such products. [ScienceInsider] Editorial
| |
EVENTSNEW 2017 Gastrointestinal Cancers Symposium Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Vice President – Legacy Research Institute (Legacy Health) Postdoctoral Researcher – Translational Cancer Discovery (Institute of Cancer Research) Product Specialist – Oncology (Celgene Corporation) Postdoctoral Fellow – Control and Estimation for the Artificial Pancreas (Mc Gill University) Postdoctoral Fellow – Pancreatic Stem Cell Biology (University of Southern California) Research Fellow – Genome Regulation and Diabetes (Imperial College London) Research Histotechnologist I (Fred Hutchinson Cancer Research Center) Postdoctoral Researcher – Breast, Prostate, and Pancreatic Cancer (MD Anderson Cancer Center) Postdoctoral Fellow – Pancreatic Cancer Biology (New York University School of Medicine) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 7.33 | Aug 23 2016
